How Much Does Zepbound Cost in Montana in 2026?

Montana Retail Pricing for Zepbound in 2026

The list price for Zepbound set by Eli Lilly is $1,059.87 per month, and Montana retail pharmacies charge this amount (or very close to it) for patients paying cash without insurance. This price applies across all dose strengths, from the 2.5 mg starting dose through the maximum 15 mg dose, because each carton contains four single-dose pens covering one month of weekly injections.

Montana has no state-level prescription drug price cap that would reduce this figure. Prices at independent pharmacies in Billings, Missoula, Great Falls, and Helena cluster tightly around the $1,059 mark, though minor variations of $10 to $30 may appear depending on the pharmacy's wholesale contract. Using a GoodRx or RxSaver coupon at Montana pharmacies may shave $20 to $80 off the cash price, but these discount cards do not reduce the cost meaningfully for a medication at this price point [1].

For context, the average Montana household income is approximately $66,000 per year according to U.S. Census data. At $12,719 annually, Zepbound without coverage would consume roughly 19% of pre-tax household income. That math makes insurance coverage, manufacturer assistance, or compounded alternatives a practical necessity for most Montana residents.

Insurance Coverage for Zepbound in Montana

Commercial insurance coverage for Zepbound varies sharply across Montana carriers. BlueCross BlueShield of Montana, Pacific Source, and Allegiance Benefit Plan Management each maintain their own formulary decisions, and coverage depends on the specific plan an employer has purchased.

Plans that do cover Zepbound typically require prior authorization. The standard criteria include a documented BMI of 30 or higher (or 27 with at least one weight-related comorbidity such as type 2 diabetes, hypertension, or dyslipidemia), failure of lifestyle modification for at least six months, and sometimes a trial of an older anti-obesity medication like phentermine. Step therapy requirements add weeks to the approval timeline.

"Prior authorization for anti-obesity medications should not be so burdensome that it functionally denies access," stated the Obesity Medicine Association's 2024 clinical practice guidelines. "Clinicians report that PA requirements for GLP-1 receptor agonists are among the most complex in outpatient medicine" [2].

Even with commercial insurance approval, out-of-pocket costs depend on the plan's tier placement. Zepbound sits on specialty tiers for many Montana plans, which can mean coinsurance of 25% to 50% rather than a flat copay. A patient with 30% coinsurance would still owe roughly $318 per month before reaching their deductible or out-of-pocket maximum.

Self-funded employer plans (ERISA plans) are not bound by Montana state insurance mandates. Large employers in Montana's mining, agriculture, and healthcare sectors often use self-funded arrangements, meaning coverage decisions rest with the plan administrator rather than state regulation [3].

Montana Medicaid and Zepbound

Montana Medicaid does not cover Zepbound for chronic weight management. This exclusion is consistent with the program's long-standing policy of not covering anti-obesity medications, a position shared by the majority of state Medicaid programs nationwide.

The exclusion traces back to the Medicaid Drug Rebate Program's original statutory language. While the Affordable Care Act expanded Medicaid coverage broadly, anti-obesity drugs remained in a category that states could exclude at their discretion. Montana has exercised that option. A 2024 report from the Kaiser Family Foundation found that only 14 states cover at least one GLP-1 receptor agonist for weight management under Medicaid [4].

There is one narrow exception. If a Montana Medicaid beneficiary has a separate FDA-approved indication for tirzepatide (the active ingredient in Zepbound is also marketed as Mounjaro for type 2 diabetes), the Medicaid program may cover Mounjaro under the diabetes indication. The prescribing physician must document a type 2 diabetes diagnosis, not obesity alone. This is a different product (Mounjaro, not Zepbound) with a different NDC, but the molecule is identical [5].

Montana's 2025 legislative session did not advance any bills mandating Medicaid coverage for anti-obesity medications. Advocacy groups continue to push for coverage expansion, but no legislative vehicle is pending as of mid-2026.

The Eli Lilly Savings Card in Montana

Eli Lilly offers a manufacturer savings card that reduces the out-of-pocket cost of Zepbound to as low as $25 per month for eligible patients. The card works in Montana at any participating retail pharmacy.

Eligibility requirements are specific. The patient must have commercial insurance (not Medicare, Medicaid, TRICARE, or any federal or state government plan), the insurance must either cover Zepbound or the patient must have been denied coverage, and the patient must have a valid prescription. Patients whose commercial insurance does not cover Zepbound at all can still use the savings card, but in that scenario the card covers up to $563 per month off the list price rather than reducing the copay to $25 [6].

The distinction matters. A commercially insured Montana patient whose plan covers Zepbound with a $150 copay would pay $25 with the savings card. A commercially insured patient whose plan denies Zepbound entirely would pay approximately $496 per month ($1,059 minus the $563 card benefit). The savings card does not eliminate cost for uncovered patients. It reduces it.

Savings card benefits reset on a calendar-year basis. Lilly has renewed the program each year since Zepbound's November 2023 launch, but renewal is at the company's discretion. Patients should verify current terms at the Lilly website or by calling the number on the card before filling each prescription.

Compounded Tirzepatide in Montana

Compounded tirzepatide is available in Montana through licensed 503A compounding pharmacies. These pharmacies can legally compound tirzepatide because the FDA's drug shortage list included tirzepatide for an extended period during 2023 and 2024, and certain compounding exemptions remain in effect under ongoing litigation and regulatory review.

The typical cost for compounded tirzepatide in Montana ranges from $199 to $349 per month depending on the pharmacy, dose, and whether the formulation is a single-dose vial or multi-dose vial. The median price across major telehealth-connected compounding services is approximately $249 per month.

Several points deserve attention. Compounded tirzepatide is not FDA-approved. It is not bioequivalent-tested against Zepbound in the way a generic drug would be. The FDA has issued warning letters to compounding pharmacies making products that do not meet Current Good Manufacturing Practice standards [7]. Montana's Board of Pharmacy oversees 503A pharmacies operating within state lines, but oversight capacity varies.

"Patients considering compounded peptides should verify that the pharmacy holds a current state license and uses USP-compliant sterility testing," noted the American Association of Clinical Endocrinology's 2023 guidance on compounded peptides [8]. A reputable 503A pharmacy will provide a certificate of analysis for each batch upon request.

Montana does not have state-specific legislation banning or restricting compounded tirzepatide beyond federal regulations. Patients in rural Montana communities where retail pharmacy options are limited often rely on mail-order compounding services, which ship to Montana addresses legally under the 503A framework as long as the prescription originates from a valid patient-prescriber relationship.

Telehealth Access to Zepbound in Montana

Montana allows telehealth prescribing of Zepbound and compounded tirzepatide. The Montana Board of Medical Examiners permits prescribers to establish a patient-provider relationship via synchronous video or audio visit, which satisfies the requirement for prescribing scheduled and non-scheduled medications.

Multiple national telehealth platforms operate in Montana and can prescribe Zepbound or connect patients with compounding pharmacy services. The telehealth visit itself typically costs $50 to $149, depending on the platform and whether an ongoing subscription model is used. Some platforms bundle the telehealth consultation fee into the monthly medication cost.

For Montana residents outside the Billings, Missoula, and Great Falls metro areas, telehealth may be the most practical route to obesity medicine specialty care. Montana ranks 49th among U.S. states in physicians per capita according to AAMC physician workforce data, and board-certified obesity medicine specialists are concentrated in urban centers [9]. Telehealth bridges that geographic gap.

The Ryan Haight Act requires that prescribing of controlled substances via telehealth include at least one in-person evaluation, but tirzepatide is not a controlled substance. No in-person visit is required before a Montana prescriber writes a Zepbound prescription via telehealth [10].

Clinical Efficacy: What SURMOUNT-1 Showed

The key trial supporting Zepbound's FDA approval was SURMOUNT-1, a 72-week randomized, double-blind, placebo-controlled study enrolling 2,539 adults with obesity or overweight with at least one weight-related comorbidity (excluding diabetes). Participants received tirzepatide at 5 mg, 10 mg, or 15 mg, or placebo, administered once weekly by subcutaneous injection [1].

Results were striking. The 15 mg group lost 22.5% of body weight on average at 72 weeks. The 10 mg group lost 21.4%. The 5 mg group lost 16.0%. Placebo produced 3.1% loss. More than one in three participants on the 15 mg dose achieved ≥25% body weight reduction, a threshold previously associated only with bariatric surgery outcomes [1].

SURMOUNT-2, published in The Lancet, studied tirzepatide specifically in adults with type 2 diabetes and obesity. The 15 mg dose produced 14.7% mean weight loss at 72 weeks in that population, with simultaneous HbA1c reductions of 2.1 percentage points [11].

The SURMOUNT-4 trial examined weight regain after discontinuation. Participants who switched from tirzepatide to placebo after 36 weeks regained approximately 14% of body weight over the following 52 weeks, while those continuing tirzepatide maintained their loss. This finding underscores that tirzepatide, like other anti-obesity medications, requires ongoing use to sustain benefit [12].

Side Effects and Dose Titration

Gastrointestinal side effects are the most common adverse events with Zepbound. In SURMOUNT-1, nausea occurred in 24% to 33% of tirzepatide-treated participants (depending on dose) versus 9.5% with placebo. Diarrhea affected 18% to 23%. Constipation occurred in 11% to 17%. Most GI events were mild to moderate and occurred during dose escalation [1].

The standard titration schedule starts at 2.5 mg weekly for four weeks, then increases to 5 mg. Subsequent increases by 2.5 mg increments occur every four weeks based on tolerability, up to the maximum 15 mg dose. Full titration takes at least 20 weeks. Rushing the titration increases GI side effect severity [13].

Serious but rare adverse events in the Zepbound clinical program included pancreatitis (reported in <0.2% of participants), gallbladder events, and hypoglycemia when used concomitantly with insulin or sulfonylureas. Zepbound carries a boxed warning about thyroid C-cell tumors based on animal studies with GLP-1 receptor agonists, though no causal link has been established in humans [13].

Practical Cost-Reduction Strategies for Montana Patients

Montana residents seeking the lowest effective cost for tirzepatide have several concrete options to evaluate.

Commercial insurance with savings card. If your employer plan covers Zepbound, the Lilly savings card drops your copay to $25 monthly. This is the cheapest legitimate route. Call your insurer's pharmacy benefit line and ask for the prior authorization criteria before your prescriber submits the request.

Appeal a denial. If your commercial plan denies coverage, file a formal appeal. Include your prescriber's letter of medical necessity, documentation of BMI and comorbidities, and evidence of prior lifestyle intervention. Montana insurance regulations require insurers to respond to appeals within 30 business days for non-urgent requests.

Compounded tirzepatide. At approximately $249 per month, compounded tirzepatide from a licensed 503A pharmacy costs roughly 76% less than the brand-name product. Confirm the pharmacy's Montana Board of Pharmacy license and ask for batch-specific certificates of analysis.

Patient assistance programs. Eli Lilly's Zepbound patient assistance program (separate from the savings card) provides the medication at no cost to uninsured patients with household income below 400% of the federal poverty level. For a single-person household in 2026, that threshold is approximately $62,400 [6].

Flexible spending / HSA accounts. Zepbound is an eligible expense for FSA and HSA reimbursement when prescribed for an FDA-approved indication. Using pre-tax dollars effectively reduces cost by the patient's marginal tax rate.